Search results

ANSTO's Chief Nuclear Officer shares insights on the safe management of Australia's nuclear waste.

ANSTO has almost seventy years of experience in advancing an understanding of the management of spent nuclear fuel and delivering safe and reliable forms for radioactive waste. 

ANSTO has safely managed its radioactive waste for over 60 years. Waste is managed in accordance with national and international standards.

ANSTO has over 35 years' experience in providing radiation safety management with teams offering radiation consultancy, instrument calibration and radiation safety training tailored to our clients' needs.

ANSTO has released the Independent Safety Review of Building 23 - Nuclear medicine production facility.

In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.

Frequently asked questions about ANSTO for the community.

The new trilateral security partnership between Australia, the UK and the US (AUKUS) is a historically significant development for nuclear science and technology in Australia. 

The final report on the safety of Building 23 by the independent expert review team has been completed.

An accomplished international photographer has capture dazzling new images of one component of the main ring at our Australian Synchrotron and provided an inside view of the electron’s path when it is used.

Combining scientific expertise with more than $1.3 billion in unique operational assets to provide optimal radioactive waste solutions.

Over the past 70 years ANSTO has been building Australia’s nuclear expertise and despite being small in scale, today we are complex and sophisticated nuclear nation.

Radioisotopes are widely used in medicine, industry, and scientific research. New applications for radioisotopes are constantly being developed.

Australian clean energy technology company, entX Limited is taking advantage of ANSTO’s unique capacity to generate tailored radioisotope products in the OPAL multi-purpose nuclear reactor to advance a series of innovative projects.

The IAEA is providing $1.3m over four years to implement a new, Australian-led patient-care project for the Asia and Pacific region